Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Colorectal Neoplasms 18Carcinoma, Non-Small-Cell Lung 14Breast Neoplasms 14Lung Neoplasms 12Head and Neck Neoplasms 10Rectal Neoplasms 8Prostatic Neoplasms 7Mouth Neoplasms 5Glioblastoma 5Esophageal Neoplasms 5Colonic Neoplasms 5Central Nervous System Neoplasms 5Pancreatic Neoplasms 4Oropharyngeal Neoplasms 4Neoplasm Metastasis 4Hypopharyngeal Neoplasms 4Gliosarcoma 4Carcinoma 4Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Ovarian Neoplasms 3Neuroblastoma 3Neoplasms 3Laryngeal Neoplasms 3Brain Neoplasms 3Uterine Cervical Dysplasia 2Turcot syndrome 2Tongue Neoplasms 2Salivary Gland Neoplasms 2Recurrence 2

Interventions

Dexamethasone 11Lenalidomide 9Calcium Dobesilate 5carfilzomib 4daratumumab 3isatuximab 2iberdomide 2elotuzumab 2dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Leflunomide 2Denosumab 2selinexor 1pomalidomide 1piperine 1ixazomib 1ibrutinib 1fludarabine phosphate 1fludarabine 1Simvastatin 1Nivolumab 1Metformin 1Melphalan 1IPH-2101 1Gene Expression Profiling 1Fatty Acids, Omega-3 1Cyclophosphamide 1Curcumin 1Cholestyramine Resin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Smoldering Multiple Myeloma × Celecoxib × Clear all
NCT00099047 2016-12-30

Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
23 enrolled 7 charts
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡